Keratinocytes produce a molecule, epidermal-derived thymocyte activating factor (ETAF), which is biologically and physiochemically similar to the polypeptide hormone interleukin 1 (IL-1). Because the stratum corneum (SC) is composed of terminally differentiated keratinocytes, we questioned whether ETAF/IL-1 could be isolated from this tissue. The extraction of normal human SC with a physiologic saline solution yielded a large amount of ETAF/IL-1 activity, as measured by the in vitro thymocyte co-stimulator assay. SC-derived ETAF/IL-1 (scETAF/IL-1) eluted from a sizing column with an approximate molecular weight of 15,000, and demonstrated three isoelectric point forms after separation on a chromatofocusing column. By these physiochemical characteristics, scETAF/IL-1 was found to be similar, if not identical to human keratinocyte-and macrophage-derived ETAF/IL-1. Further, a number of biologic effects known to occur in vivo after the administration of ETAF/ IL-1, such as fever, neutrophilia, and an increase in plasma levels of acute-phase proteins, were all induced by the injection of scETAF/IL-1 into endotoxin-nonresponsive mice. scETAF/IL-1 was also found to stimulate collagenase production by human fibroblasts in vitro. In summary, our studies have established that normal human SC contains a large quantity of scETAF/IL-1. Whether scETAF/IL-1 integrates into the earliest afferents phases of local inflammatory responses, or merely represents a means of disposal of excessively produced hormone is currently unresolved.
Introduction
A considerable amount of investigative effort has recently been spent on the analysis of interleukin I (IL-i),' a hormone that mediates a wide range of biologic effects in vivo and in vitro. IL-I is a 1 5,000-mol wt polypeptide reported to play an integral role in the generation of both immune and inflammatory responses (1) (2) (3) . Pyrogenicity, neutrophil chemotaxis, lymphocyte activation and chemotaxis, muscle proteolysis, and the production of acute-phase proteins are all effects induced by the action of IL-I on various anatomic sites including the brain, bone mar-1. Appreviations used in this paper: ETAF, epidermal-derived thymocyte activating factor; IL-1, interleukin 1; LPS, lipopolysaccharide; pI, isoelectric point; PMA, phorbol myristate acetate; SAP, serum amyloid P (substance); SC, stratum corneum. row, lymphoid tissue, muscle, and liver (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Once believed to be produced only by activated macrophages, the synthesis and secretion of IL-1 or IL-1-like molecules has now been extended to a variety of cell types, including keratinocytes of the skin (15, 16) . Because ofits cellular source, keratinocyte-derived IL-1 was originally termed epidermal-derived thymocyte activating factor (ETAF). However, we now appreciate that ETAF and IL-1 are physiochemically similar and share most biologic activities ( 17) .
Keratinocytes originate in the basal, germinative layer ofthe epidermis and terminally differentiate to form eventually the cells of the outermost layer of the skin known as the stratum corneum (SC). Dalziel et al. (18) recently established that sterile human SC, implanted intracutaneously into guinea pigs, induced a pronounced inflammatory response suggesting that a pro-inflammatory mediator might associate with this material. Preliminary observations in our laboratory determined that a significant amount ofin vitro thymocyte co-stimulator activity was present on the surface of normal human skin. We therefore undertook an investigation to establish whether this bioactivity was associated with substances present within the stratum corneum. Herein we report that normal human stratum corneum contains a large amount of easily extractable ETAF/IL-1 activity. This substance(s) demonstrates the approximate molecular weight, isoelectric points, heat stability, as well as in vitro and in vivo bioactivities of human keratinocyte-and macrophage-derived scalpel blade or by using a Dr. Scholl's callus remover. Immediately after collection the SC was snap-frozen in liquid nitrogen and pulverized to a fine powder with a mortar and pestle. The SC was then extracted by adding 10 ml of PBS for each gram of powdered SC, followed by homogenization for 30 s with a Polytron Tissue Homogenizer (Brinkmann Instruments, Inc., Westbury, NY). The insoluble material was pelleted by centrifugation and the supernatant was collected. This extraction process was then repeated one to four additional times. The protein content of each extract was determined by the Lowry assay using a bovine plasma gamma globulin protein standard (Bio-Rad Laboratories, Richmond, CA). Any deviation from the protocol outlined above is explained in the Results section.
Bioassays employed to detect the presence of ETAF/IL-1 in vitro analysis. The thymocyte co-stimulator assay has become a standard test for the presence of ETAF/IL-I and measures the ability ofthis mediator to augment mitogen-induced proliferation of murine thymocytes. Serial dilutions (in triplicate) oftest and standard supernatants were incubated with 5 X lO peanut agglutinin (Arachis hypogaea, Sigma Chemical Co., St. Louis, MO) negative thymocytes in RPMI-1640 containing 1% normal mouse serum (plus 5 U/ml penicillin, 50 Mg/ml streptomycin, 2 mM glutamine, 5 X 10-0 M 2-mercaptoethanol and non-essential amino acids) in the presence or absence 2.5 gg/ml of phytohemagglutinin (Sigma Chemical Co.). After 66 h at 370C in 5% C02, cell cultures were pulsed with 0.5 MCi of [3H]thymidine (2 Ci/mM, New England Nuclear, Boston, MA) and then harvested 6 h later onto glass fiber filters (PhD cell harvester, Cambridge Technology, Inc., Cambridge, MA).
A second in vitro assay, recently described by Kaye et al. (20, 21) , employs an ETAF/IL-I-responsive T lymphocyte cell line as a reliable indicator for the presence ofETAF/IL-I in test and standard supernatants. Serial dilutions, in triplicate, of a supernatant were incubated with 1 X I04 DIO.G4.1 cells in cRPMI-1640 media containing 5% fetal calf serum in the presence or absence of2.5 ,g/ml ofconcanavalin A (Sigma Chemical Co.). Cultures were pulsed with 0.5 MCi of [3H]thymidine for the final 6 h of a 48-h incubation period and harvested, as described above, prior to counting with a scintillation counter (Packard Instrument Co., Inc., Downers Grove, IL).
Neither the C3H/HeJ thymocytes nor the DlO.G4.1 cells respond significantly to 2.5 ug/ml of mitogen in the absence of ETAF/IL-I or to the test supernatants (or ETAF/IL-I standards) in the absence of mitogen. Therefore, both of these in vitro assays measure the ability of ETAF/ IL-I to augment (or co-stimulate) cellular proliferation induced by mitogen. In our assays, 1 U of ETAF/IL-l is capable of increasing the proliferative rate ofmurine thymocytes 10-15-fold, whereas 1 U of ETAF/ IL-I induces a 30-50-fold increase in DlO.G4. 1 Collagenase production by humanfibroblasts in vitro. The ability of scETAF/IL-I to stimulate collagenase production by human skin fibroblasts (2-mo-old donor, sixth passage) was assessed employing a procedure described in detail elsewhere (22 Plasma obtained from mice 24 h postinjection of the test SC extract was assayed quantitatively for serum amyloid-P (SAP) by radial immunodiffusion employing a rabbit anti-murine SAP antibody.
Physiochemical characterization of IL-I-containing supernatants.
1 ml ofa crude SC extract was applied to a 1.6 X 65-cm column containing ACA 54 (Pharmacia Fine Chemicals, Piscataway, NJ). This column was preequilibrated with Dulbecco's PBS containing 50 U/ml of penicillin and 50 ,g/ml of streptomycin. The column was run at a flow rate of 6.0 ml/h and I.0-ml fractions were collected. 20 Ml of each column fraction was directly evaluated for ETAF/IL-l activity in both the DlO.G4. 1 and thymocyte bioassays.
Chromatofocusing was employed to determine the isoelectric point(s) of the material from human SC extracts having ETAF/IL1-activity by means of a technique described in detail in the Pharmacia instruction booklet ("Chromatofocusing with Polybuffer and PBE," Pharmacia Fine Chemicals, Uppsala, Sweden). The crude SC extract or the 15,000-mol wt fraction from the ACA 54 column was initially dialyzed against the starting buffer (0.025 M Tris-CH3COOH, pH 8.3) followed by its application to a 0.5 X 30-cm column containing the polybuffer exchanger PBE 94 (Pharmacia Fine Chemicals, Uppsala, Sweden) which was preequilibrated with the starting buffer. A gradient was formed between the pHs of 5 and 8 using the starting and elution buffers recommended for this pH range in the Pharmacia Chromatofocusing instructions. 2-ml fractions were collected and 1-10 ,ul ofeach column fraction was directly tested for ETAF/IL-1 activity using the thymocyte and DIO.G4.1 costimulator assays. The protein content ofpooled chromatofocusing fractions was determined by employing the Bradford reagent because the polybuffers employed in this procedure interfere with the Lowry assay.
Results
Analysis of the soluble proteins extracted from SC for ETAF/ IL-1 activity in vitro. A cell-free supernatant derived from pooled sequential extractions of a l-g sample of SC was tested for the presence of ETAF/IL-1 by the DlO.G4.1 and thymocyte costimulator assays. Fig. 1 represents the results obtained using the DIO.G4.1 bioassay and demonstrates that the SC extract tested contained a large amount of co-stimulator activity. In terms of units, the SC supernatant possessed -16,000 U/ml of ETAF/IL-1 activity or '-4 X 105 U/g of original SC. An equivalent amount of co-stimulator activity was detected by the thymocyte bioassay (data not shown). In the absence of mitogen, the supernatant had no stimulatory effect on either the DlO.G4. 1 cells or murine thymocytes. Protein content in this pooled SC extract was determined by the Lowry assay to be -1.7 mg/ml. Therefore, 4. amounts of several other fresh tissues including heart muscle, lung, spleen, and kidney did not yield any ETAF/IL-1 activity.
In an attempt to eliminate the possibility that products from a bacterial contamination in the SC extract were responsible for inducing the cellular proliferation, scETAF/IL-1 was also extracted from a source of SC (vernex) aseptically removed from a newborn infant immediately after delivery by cesarean section. The soluble extract derived from vernex demonstrated a positive co-stimulator activity (data not shown). Further, we found that exposure of scETAF/IL-l to 80°C for 10 min before in vitro analysis abrogated all co-stimulator activity (Fig. 1) . The results of these experiments suggest that the ETAF/IL-1 activity obtained from SC was not due to bacterial endotoxin contamination because endotoxin is highly resistant to heat inactivation and should not be a contaminate ofaseptically collected vernex.
The amount of scETAF/IL-1 and soluble protein that could be obtained from each extraction of a defined amount of SC was determined by a series of sequential treatments. A total of 44 mg of soluble protein and -7.0 X 105 U of scETAF/IL-l could be obtained from a 1.0-g sample of SC (data not shown). The majority of the soluble protein (87%) and scETAF/IL-1 activity (93%) was solubilized from the first two extractions. In order to obtain an equivalent amount of ETAF/IL-1 from conventionally employed ETAF/IL-1-producing cells, one would require a 100% yield in the recovery of activity from -7 liters oftissue culture supernatant. Because the loss of activity through purification and concentration procedures is quite significant (25, 26) , it is realistic to assume that one would have to start with even greater initial volumes of tissue culture supernatants to derive the amount of ETAF/IL-1 activity that can be easily obtained from a small amount of human SC.
Physiochemical analysis ofscETAF/IL-J. A sample of human scETAF/IL-1 was subjected to ACA 54 column chromatography to determine the approximate molecular weight associated with its in vitro co-stimulator activity. The results of this experiment are presented in Fig. 2 . All of the scETAF/ IL-1 bioactivity eluted from the ACA 54 column in fractions that indicate an approximate mol wt of 15,000. This result is consistent with the reported size of the major species of human ETAF/IL-I obtained from conventional cell culture sources (1, 25, 26) . In that human IL-2 demonstrates a mol wt of 15, 000 and may also possess co-mitogenic activity in vitro, we tested our scETAF/IL-1 on an IL-2-addicted murine T cell line (HT2). We found that neither the unfractionated SC extract nor the 15,000-mol wt molecule(s) derived from this preparation was capable of supporting the proliferation HT2 cells in vitro (data not shown).
Isoelectric point (pI) analysis of human ETAF/IL-I has suggested that three distinct pI forms exist (7.0-7.2, 6.6-6.8, and 5.0-5.4) (1, 25, 26) . The results of our pI analysis of human scETAF/IL-1 are shown in Fig. 3 . Employing a chromatofocusing column set up to separate molecules over a pH range of between 8 and 5, three pI forms (7.2, 6.6, and 5.0) of co-stimulator activity eluted from the column. Results obtained by directly testing column fractions in the D1O.G4. 1 bioassay suggests that the major peak of co-stimulator activity has a pI of 7.2. However, when peaks of activity were pooled separately and dialyzed to remove the chromatofocusing buffers, an equivalent amount of co-stimulator activity was present in each of the peaks (data not shown).
The data presented in Table I represent the scheme employed to semipurify scETAF/IL-1 from a 1 .0-g sample of normal SC. Dialysis of the crude SC extract against a low molarity Tris- Figure 2 . Determination of the approximate molecular weight of sc-ETAF/IL-1. A I -ml sample of SC extract demonstrating in vitro costimulator activity (-1000 U/ml) was subjected to column chromatography as described in Methods. The molecular weight standards employed were ovalbumin (44,000), myoglobin (18,800), cytochrome c (12,384) and vitamin B12 (1, 355 Figure 3 . pl analysis of scETAF/IL-1. -1,000 U of scETAF/IL-I was subjected to chromatofocusing between the range of pH 8 and 5 (A). l-ml fractions were collected and 5 gl of each fraction (in triplicate) was analyzed directly for in vitro co-stimulator activity employing DlO.G4.1 cells. Co-stimulator activity is represented as counts per minute (A). Peaks with co-stimulator activity were pooled separately and dialyzed against RPMI-1640 before retesting. All three peaks (pH 7.2, 6.6, and 5.0) contained equivalent amounts of co-stimulator activity after dialysis (data not shown). Human ETAF/IL-I from a human cell line (A43 1) subjected to pI analysis employing this technique also demonstrated three pI forms corresponding to pH 5.0-5.2, 6.6-6.8, and 7.0-7.2.
containing buffer resulted in the spontaneous precipitation of the majority of protein. Keratohyalins found in SC are reported to precipitate under these conditions (27) . Our results demonstrate that the specific activity of scETAF/IL-1 increases throughout the procedures employed for purification except the molecule(s) with the lowest pl. The pH range employed for the chromatofocusing was apparently not optimal for separation of The following experiment was conducted to determine whether scETAF/IL-I exhibits in vivo stimulatory activity on a number of diverse IL-I sensitive targets. A defined amount (established by in vitro analysis) of scETAF/IL-I was injected intravenously into C57BL/I0ScN mice which are genetically nonresponsive to lipopolysaccharide. Core body temperature was analyzed after 20 min and found to be elevated (a response that returned to normal by 2 h), blood samples were collected after 8 h and found to-contain elevated numbers of circulating neutrophils, and plasma samples, collected after 24 h, determined that the circulating level of SAP, a major murine acute-phase protein, was significantly elevated (Table II) . Pretreatment of the scETAF/ IL-I with heat (800C for 10 min) before intravenous injection abrogated all in vivo bioactivity. A 1 5,000-mol wt preparation (by ACA column chromatography) of scETAF/IL-1 was also capable ofeliciting each ofthese in vivo biologic effects. Clearly, scETAF/IL-I exhibits biologic identity with human ETAF/ IL-I by its ability to elevate core body temperature (pyrogenicity), increase the number of circulating neutrophils (neutrophil-releasing activity), and elevate the concentration of an acute-phase protein (induction of acute-phase protein activity).
The heterogeneous nature ofthe pI forms ofETAF/IL-I has been the subject of several recent reports. This heterogeneous nature is not due to differences in the glycosylation of the molecule (37) and each of the human pI forms has been reported to possess equivalent in vitro and in vivo biologic activity (38) . When a defined amount of each of the isolated pI forms of scETAF/IL-l was injected into groups of C57BL/lOScN mice, an elevation in core body temperature, peripheral blood neutrophils, and SAP concentrations were observed (Table II) .
Stimulation ofcollagenase production in vitro. The possible biologic relevance ofscETAF/IL-l in normal human SC is presently unknown; however, in light of the known properties of this mediator, one could speculate that it may integrate into the earliest events following wounding ofthe skin. One ofthe properties of ETAF/IL-1 is its ability to induce the production of collagenase by fibroblasts (31) (32) (33) (34) , an event associated with inflammation. We investigated the ability of scETAF/IL-1 to induce collagenase production by cultured human skin fibroblasts.
The results shown in Fig. 4 demonstrate that the 1 5,000-mol wt Figure 4 . Stimulation of human fibroblast skin collagenase by sc-ETAF/IL-l1. Confluent fibroblast cultures were treated for 24 h with PMA (10 ng/ml), 100 U/ml of 15,000-mol wt scETAF/IL, 100 U/ml of 15,000-mol wt (p1 7.0-7.2), 100 U/ml of 15,000-mol wt (pJ 6.6-6.8), or 100 U/ml 15,000-mol wt (p1 5. (16) observed that keratinocytes can produce a molecule termed the "epidermal-derived thymocyte activating factor" (ETAF), which was similar in function and physiochemical characteristics to macrophage derived IL-1 (17) . It is now appreciated that keratinocytes represent the major producers of this polypeptide hormone in the skin. We have previously reported that normal keratinocytes produce a significant amount of ETAF/IL-1 constitutively when maintained in vitro (45). It is also appreciated that ETAF/IL-I production can be augmented by the addition of exogenous inducers of inflammation to cell cultures or by exposure of keratinocytes to the effects of ultraviolet radiation in vitro (15) (16) (17) 45) . Furthermore, the exposure ofanimals to ultraviolet radiation in vivo results in a pronounced inflammatory response, which is accompanied by an elevation in peripheral blood neutrophils, an increase in the plasma concentration of several acute phase proteins, and the presence of detectable levels of ETAF/IL-I in the serum (45). It has been observed that subcutaneous implantation ofsterile human SC into guinea pigs results in a marked inflammation which is followed by granuloma formation (18) . Therefore, the object of this investigation was to determine whether the underlying mechanism(s) responsible for this inflammatory response might be due to the presence ofpreformed pools ofETAF/ IL-I within the SC inoculum. Our experiments demonstrate that the extraction of SC with physiologic saline yields a soluble pro-tein-containing supernatant having significant ETAF/IL-1 activity. scETAF/IL-1 was assessed in vitro by its ability to costimulate the proliferation ofboth a cloned IL-1-responsive murine T-cell line as well as murine thymocytes derived from LPS. nonresponsive donors. Further support for the concept that scETAF/IL-I and ETAF/IL-1 were similar was obtained when the co-stimulator activity demonstrated heat lability, molecular weight, and isoelectric points that were consistent with the properties of keratinocyte-and macrophage-derived human ETAF/ IL-1 (1) . Our results also demonstrate that scETAF/IL-1 and each of the isoelectric forms of this mediator are capable of inducing a significant increase in collagenase production by normal human fibroblasts in vitro.
IL-1 has been functionally defined by its ability to stimulate a variety of target-cell specific responses in vivo (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . These include pyrogenicity, the ability to induce neutrophilia, and the stimulation of liver hepatocytes to produce acute-phase proteins. We established that each of these effects could be induced by the injection of scETAF/IL-1 into LPS non-responsive mice. Further, the kinetics of the scETAF/IL-1-induced effects was consistent with their being mediated by ETAF/IL-1 and not an unknown exogenous stimulant. Therefore, the results obtained from both in vivo and in vitro analysis of SC extracts suggest that a molecule is present in SC, which funcitonally and physiochemically is similar to human ETAF/IL-1.
The SC is known to serve many homeostatic functions including the ability to absorb ultraviolet radiation from the sun, retain water within the body, and act as a major diffusion barrier to prevent potentially toxic molecules from gaining entrance. Percutaneous absorption studies have demonstrated that small lipophilic molecules can readily penetrate through SC and gain entrance to the circulation whereas the penetration ofionic molecules is greatly impeded. Increasing the hydration of SC, exposure of skin to ultraviolet radiation, or topical application of a number of substances can increase the rate of percutaneous absorption (46) . It has also been demonstrated that SC has the capacity to act as a reservoir for some lipid-soluble molecules (47, 48). For example, the topical application of hydrocortisone results in the slow release of this substance for as long as 7 d, an effect that can be abrogated by stripping the skin of stratum corneum (47).
The amount of scETAF/IL-1 that can be extracted from SC might suggest that this structure is functioning as a reservoir of this mediator (in either secreted or membrane-associated form).
Recent evidence from our laboratory suggests that normal keratinocytes appear to express ETAF/IL-1 constitutively on their plasma membrane surface (Gahring and Daynes, manuscript in preparation). Ifwe hypothesize that keratinocytes constitutively produce this mediator (or constitutively express membrane-associated forms), the presence of scETAF/IL-1 may represent a means by which excesses ofthis hormone are externalized. Other investigators have also been interested in the means by which IL-1 is removed from the body. Kimball et al. (49) have recently demonstrated that small quantities of IL-1 (ETAF/IL-1) could be detected in normal human urine after concentration and dialysis. Therefore, passage through the kidneys followed by excretion may represent a means by which IL-1 is externalized. The body is also capable of removing substances via sweat. We have preliminary evidence to suggest that human sweat contains a significant co-stimulator activity when tested in vitro after extensive dialysis. This co-stimulator activity may in fact be scETAF/IL-I derived from the hydration and release from the SC. The spontaneous elution of scETAF/IL-I into fluid medium may also be responsible for our observation that in vitro costimulator activity could be detected in normal amniotic fluid obtained from a number of individuals (unpublished observations). The amount of co-stimulator activity obtained from the extraction of normal human stratum corneum far exceeds any activity obtained from urine, sweat, or amniotic fluid and may represent a major site of ETAF/IL-I disposal.
Considering the quantity of scETAF/IL-I found in stratum corneum, several intriguing possibilities for a functional role for this molecule in wound healing could be hypothesized. Immune potentiating, chemotactic (neutrophil and T-lymphocyte), and autocrine functions of IL-I have all been described (50). Further, IL-I is known to induce fibroblasts to produce collagenase and E-series prostaglandins (31) (32) (33) (34) . If scETAF/IL-I is released into a local site after wounding, inflammatory and immune processes known to require IL-I could be immediately initiated without the lag period required for the de novo synthesis and release of this mediator by viable cells. Whether scETAF/IL-1 proves to be the inflammatory mediator responsible for the effects observed after the subcutaneous implantation of human SC into guinea pigs awaits further experimentation. The large amount of ETAF/ IL-I activity present in normal SC, coupled with the knowledge that this mediator is a known and essential inducer of inflammatory responses, indicates that scETAF/IL-1 and its potential involvement in homeostatic mechanisms warrant further investigation.
